AWP
RXRX icon

Ascent Wealth Partners’s Recursion Pharmaceuticals RXRX Stock Holding History

Ascent Wealth Partners’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$130K Buy
35,484
+7,403
+26% +$24.6K 0.01% 199
2026
Q1 		$86.2K Buy
28,081
+2,974
+12% +$11.5K 0.01% 187
2025
Q4 		$103K Buy
25,107
+3,336
+15% +$16.5K 0.01% 181
2025
Q3 		$106K Buy
21,771
+4,275
+24% +$22.5K 0.01% 179
2025
Q2 		$88.5K Buy
+17,496
New +$86K 0.01% 171

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Ascent Wealth Partners's RXRX Position: Q2 2026 in Review

Ascent Wealth Partners increased its Recursion Pharmaceuticals (RXRX) stake by 26% in Q2 2026, buying an estimated $24.6K and bringing the position to 35,484 shares worth $130K. The position accounts for 0.01% of the portfolio, ranked #199.

Ascent Wealth Partners first reported a position in RXRX in Q2 2025 and has held it in 5 quarters since. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Ascent Wealth Partners held 35,484 shares of Recursion Pharmaceuticals worth $130K as of Q2 2026.
  • Ascent Wealth Partners bought 7,403 Recursion Pharmaceuticals shares in Q2 2026, an estimated $24.6K.
  • Recursion Pharmaceuticals made up 0.01% of Ascent Wealth Partners's portfolio in Q2 2026, its #199 holding.
  • Ascent Wealth Partners first reported a position in Recursion Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Ascent Wealth Partners's 13F filing for Q2 2026, filed 31 Jul 2026.